{"id":"W2326074019","doi":"10.1177/095632020401500302","title":"Clinical Utility of Current NNRTIs and Perspectives of New Agents in This Class under Development","year":2004,"lang":"en","type":"review","venue":"Antiviral chemistry & chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Valeant Pharmaceuticals International; Bristol-Myers Squibb; Boehringer Ingelheim","keywords":"Nucleoside Reverse Transcriptase Inhibitor; Reverse transcriptase; Dosing; Protease inhibitor (pharmacology); Virology; Reverse-transcriptase inhibitor; Pharmacology; Human immunodeficiency virus (HIV); ANTIRETROVIRAL AGENTS; Medicine; Biology; Antiretroviral therapy; Viral load; Genetics; RNA","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003318973,0.0005532899,0.00244574,0.00009607481,0.00002573261,0.000008180528,0.0001716854,0.000404583,0.0004478077],"category_scores_gemma":[0.00004123309,0.0004424751,0.0004871306,0.0003158388,0.0002602431,0.00004489733,0.00007486134,0.0005040848,0.000009906506],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002723178,"about_ca_system_score_gemma":0.002075159,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001501385,"about_ca_topic_score_gemma":0.000003124263,"domain_scores_codex":[0.9971625,0.00005418845,0.001388201,0.0007052781,0.0003797999,0.0003100191],"domain_scores_gemma":[0.998704,0.00008832267,0.0005743402,0.0004041584,0.00007774323,0.0001514216],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00009656732,0.00139953,0.008774019,0.01777824,0.0008398574,0.00001670278,0.001248106,1.061147e-8,0.00002867004,0.000006824337,0.0007839156,0.9690276],"study_design_scores_gemma":[0.006349781,0.00008217363,0.007276914,0.03880522,0.0007334417,0.00002901124,0.0002980382,0.000002109034,0.009437346,0.00007762277,0.9361725,0.0007358384],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.02612113,0.9708664,0.00001623148,0.0001522305,0.00005897727,0.0007116177,0.00001444644,0.00002390537,0.002035026],"genre_scores_gemma":[0.01419359,0.9801219,0.0009555179,0.00001432316,0.00008467088,0.00001938261,0.0001188274,0.00005022742,0.004441522],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9682917,"threshold_uncertainty_score":0.9998027,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1243724358799134,"score_gpt":0.4137304869345004,"score_spread":0.289358051054587,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}